Literature DB >> 30790593

Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)8-paclitaxel prodrug: In Vivo conversion and antitumor efficacy.

Yu Tong Tam1, Dae Hwan Shin1, Karen E Chen1, Glen S Kwon2.   

Abstract

Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles affect drug solubilization, and a paclitaxel (PTX) loaded-PEG-b-PLA micelle (PTX-PM) is approved for cancer treatment due to injection safety and dose escalation (Genexol-PM®) compared to Taxol®. However, PTX-PM is unstable in blood, has rapid clearance, and causes dose-limiting toxicity. We have synthesized a prodrug for PTX (7-OH), using oligo(lactic acid) as a novel pro-moiety (o(LA)8-PTX) specifically for PEG-b-PLA micelles, gaining higher loading and slower release of o(LA)8-PTX over PTX. Notably, o(LA)8-PTX prodrug converts into PTX by a backbiting reaction in vitro, without requiring esterases. We hypothesize that o(LA)8-PTX-loaded PEG-b-PLA micelles (o(LA)8-PTX-PM) has a lower Cmax and higher plasma AUC than PTX-PM for improved therapeutic effectiveness. In Sprague-Dawley rats at 10 mg/kg, compared to o(LA)8-PTX-PM (10% w/w loading) and PTX-PM (10%), o(LA)8-PTX-PM (50% w/w loading) produces a 2- and 3-fold higher plasma AUC0-24 of PTX, lactic acid-PTX, and o(LA)2-PTX (o(LA)0-2-PTX), respectively. For o(LA)8-PTX-PM at 10 and 50% w/w loading, PTX and lactic acid-PTX are major bioactive metabolites, respectively. Fast prodrug conversion of o(LA)8-PTX in vivo versus in vitro (by backbiting) suggests that o(LA)8 is a good substrate for esterases. At 60 mg/kg (qwx3), o(LA)8-PTX-PM (50%) has higher antitumor activity than o(LA)8-PTX-PM (10%) and PTX-PM (10%) in a syngeneic 4T1-luc breast tumor model based on measurements of tumor volume, 4T1-luc breast tumor bioluminescence, and survival. Importantly, intravenous administration of o(LA)8-PTX-PM is well tolerated by BALB/c mice. In summary, oligo(lactic acid)8-PTX is more compatible than PTX with PEG-b-PLA micelles, more stable, and may expand the role of PEG-b-PLA micelles from "solubilizer" into "nanocarrier" for PTX as a next-generation taxane for cancer.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Block copolymer; Oligo(lactic acid); PEG; Polymeric micelle; Prodrug; Taxanes

Mesh:

Substances:

Year:  2019        PMID: 30790593      PMCID: PMC6466635          DOI: 10.1016/j.jconrel.2019.02.017

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  28 in total

Review 1.  Novel formulations of taxanes: a review. Old wine in a new bottle?

Authors:  K L Hennenfent; R Govindan
Journal:  Ann Oncol       Date:  2005-12-19       Impact factor: 32.976

2.  Insights into the mechanism of microtubule stabilization by Taxol.

Authors:  Hui Xiao; Pascal Verdier-Pinard; Narcis Fernandez-Fuentes; Berta Burd; Ruth Angeletti; Andras Fiser; Susan Band Horwitz; George A Orr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

Review 3.  Enzymes involved in the bioconversion of ester-based prodrugs.

Authors:  Bianca M Liederer; Ronald T Borchardt
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

Review 4.  Formulation of drugs in block copolymer micelles: drug loading and release.

Authors:  J Liu; H Lee; C Allen
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

5.  Hydrotropic polymer micelle system for delivery of paclitaxel.

Authors:  Kang Moo Huh; Sang Cheon Lee; Yong Woo Cho; Jaehwi Lee; Jae Hyun Jeong; Kinam Park
Journal:  J Control Release       Date:  2005-01-03       Impact factor: 9.776

6.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.

Authors:  S C Kim; D W Kim; Y H Shim; J S Bang; H S Oh; S Wan Kim; M H Seo
Journal:  J Control Release       Date:  2001-05-14       Impact factor: 9.776

7.  Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

Authors:  Keun Seok Lee; Hyun Cheol Chung; Seock Ah Im; Yeon Hee Park; Chul Soo Kim; Sung-Bae Kim; Sun Young Rha; Min Young Lee; Jungsil Ro
Journal:  Breast Cancer Res Treat       Date:  2007-05-03       Impact factor: 4.872

8.  Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

Authors:  Tae-You Kim; Dong-Wan Kim; Jae-Yong Chung; Sang Goo Shin; Sung-Chul Kim; Dae Seog Heo; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity.

Authors:  M Laird Forrest; Jaime A Yáñez; Connie M Remsberg; Yusuke Ohgami; Glen S Kwon; Neal M Davies
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

10.  Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

Authors:  D-W Kim; S-Y Kim; H-K Kim; S-W Kim; S W Shin; J S Kim; K Park; M Y Lee; D S Heo
Journal:  Ann Oncol       Date:  2007-09-04       Impact factor: 32.976

View more
  3 in total

1.  Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.

Authors:  Yongwei Gu; Juanjuan Ma; Zhiqin Fu; Youfa Xu; Baoan Gao; Jianzhong Yao; Wei Xu; Kedan Chu; Jianming Chen
Journal:  Int J Nanomedicine       Date:  2019-11-07

2.  Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.

Authors:  Jianqin Wan; Lingling Huang; Jiangting Cheng; Huangfu Qi; Jiahui Jin; Hangxiang Wang
Journal:  Theranostics       Date:  2021-02-19       Impact factor: 11.556

3.  Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer.

Authors:  Lauren Repp; Christopher J Unterberger; Zhengqing Ye; John B Feltenberger; Steven M Swanson; Paul C Marker; Glen S Kwon
Journal:  Nanomaterials (Basel)       Date:  2021-10-17       Impact factor: 5.076

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.